Filter Publications By:

01/06/2015

J. Allergy Clin. Immunol., 2001; 108:191-197.

Immunostimulatory Sequence DNA Linked to the Amb a 1 Allergen Promotes Th1 Cytokine Expression While Downregulating Th2 Cytokine Expression in PBMCs from Human Patients with Ragweed Allergy.

Marshall, J.D., S. Abtahi, J.J. Eiden, S. Tuck, R. Milley, F. Haycock, M.J. Reid, A. Kagey-Sobotka, P.S. Creticos, L.M. Lichtenstein, and G. Van Nest.

01/06/2015

J. Allergy Clin. Immunol., 2004; 113(6):1144-1151.

Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.

Simons, F.E., Y. Shikishima, G. Van Nest, J.J. Eiden, and K.T. HayGlass.

01/06/2015

BioDrugs, 2006; 6(20):335-340(6).

Evolving strategies for the prevention of influenza infection: potential for multistrain targeting.

Livingston BD, Higgins D, Van Nest G.

01/06/2015

Vaccine, 2003; 21(19-20): 2461-2467.

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.

Halperin, S.A., G. Van Nest, B. Smith, S. Abtahi, H. Whiley, and J.J. Eiden.

01/06/2015

Vaccine, 2006; 24(1): 20-26.

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.

Scott A. Halperin, Simon Dobson, Shelly McNeil, Joanne M. Langley, Bruce Smith, Robyn McCall-Sani, Dan Levitt, Gary Van Nest, Daniel Gennevois, Joseph J. Eiden.

01/06/2015

BioDrugs, 2006; 20(6):335-340.

Evolving strategies for the prevention of influenza infection: potential for multistrain targeting.

Livingston BD, Higgins D, Van Nest G.

01/06/2015

The American Journal of Medicine, 2006; 119(10):897.e1-6

TLR9-Based Immunotherapy for Allergic Disease.

Tomoko Hayashi, MD, PhD, Eyal Raz, MD.

01/06/2015

Vaccine, 2012; 30(16): 2689-2696.

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.

Benjamin P. Sablan, Dong Joon Kim, Nina G. Barzaga, Wan Cheng Chow, Mong Cho, Sang Hoon Ahn, Seong Gyu Hwang, Ji Hyun Lee, Hamid Namini, William L. Heyward.

01/06/2015

Vaccine, 2012; 30(36):5445-5448.

Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.

Scott A. Halperin, Shelly McNeil, Joanne M. Langley, Bruce Smith, Donna MacKinnon-Cameron, Robyn McCall-Sani, William L. Heyward, J. Tyler Martin.

01/06/2015

Leukemia, 2014, Jan 30. doi: 10.1038/leu.2014.46.

A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.

Ray A, Tian Z, Das DS, Coffman RL, Richardson P, Chauhan D, Anderson KC.